JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
Scope & Guideline
Advancing pediatric mental health through innovative research.
Introduction
Aims and Scopes
- Pharmacological Treatment of Psychiatric Disorders:
The journal extensively covers research related to pharmacological interventions for various psychiatric conditions such as ADHD, depression, anxiety, and psychotic disorders in children and adolescents. - Systematic Reviews and Meta-Analyses:
A significant portion of publications includes systematic reviews and meta-analyses that aggregate findings from multiple studies to provide comprehensive insights into treatment efficacy and safety. - Innovations in Psychopharmacology:
The journal highlights cutting-edge research, including novel medications and treatment protocols, contributing to the advancement of psychopharmacology in pediatric populations. - Longitudinal and Cohort Studies:
Research often employs longitudinal and cohort study designs to assess the long-term effects of psychotropic medications and their impact on developmental outcomes. - Pharmacogenomics and Personalized Medicine:
The journal increasingly focuses on pharmacogenetic studies that explore genetic factors influencing medication response, aiming to enhance personalized treatment approaches for youth. - Behavioral and Psychosocial Interventions:
In addition to pharmacological studies, the journal includes research on the integration of behavioral therapies with pharmacological treatments to optimize outcomes in youth.
Trending and Emerging
- Innovative Treatment Modalities:
There is a growing emphasis on exploring new treatment modalities, including the use of ketamine and transcranial magnetic stimulation for treatment-resistant depression, indicating a shift towards more innovative approaches in psychopharmacology. - Pharmacogenetics and Personalized Medicine:
Recent publications increasingly focus on pharmacogenetic factors that influence medication efficacy and safety, marking a significant trend towards personalized medicine in pediatric psychopharmacology. - Impact of COVID-19 on Youth Mental Health:
The journal has seen a rise in studies investigating the psychological impact of the COVID-19 pandemic on children and adolescents, emphasizing the need to address emerging mental health challenges. - Metabolic Monitoring in Psychotropic Treatment:
Research on metabolic monitoring in youth prescribed second-generation antipsychotics is becoming more prevalent, reflecting concerns about long-term health outcomes and the need for comprehensive care. - Intersection of Mental Health and Developmental Disorders:
There is an increasing trend in exploring the intersectionality of mental health issues with developmental disorders such as autism, highlighting the complexities of treatment in these populations.
Declining or Waning
- Traditional Antidepressant Studies:
Research focusing solely on traditional antidepressants, particularly SSRIs without considering adjunct therapies or novel treatments, has decreased as newer modalities gain attention. - Generalized Anxiety Disorder (GAD) Focus:
While anxiety disorders remain a topic of interest, specific studies centered on GAD alone are less frequent, possibly as a result of a broader focus on anxiety as part of a spectrum of disorders. - Pharmacotherapy for ADHD without Behavioral Interventions:
There is a noticeable decline in studies examining pharmacotherapy for ADHD in isolation, with a growing emphasis on combined treatment approaches that integrate behavioral interventions. - Longitudinal Studies on Medication Side Effects:
The frequency of studies specifically focusing on long-term side effects of established medications is decreasing, potentially due to a shift towards understanding efficacy in broader treatment contexts.
Similar Journals
Therapeutic Advances in Psychopharmacology
Transforming Research into Therapeutic BreakthroughsTherapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.
Brazilian Journal of Psychiatry
Bridging the gap between research and clinical practice.The Brazilian Journal of Psychiatry is a prominent peer-reviewed journal dedicated to advancing the field of psychiatry and mental health, published by the Associação Brasileira de Psiquiatria. With an impressive Q2 ranking in the Psychiatry and Mental Health category for 2023 and a Scopus rank of #130 out of 567, this journal serves as a vital resource for researchers, clinicians, and students alike. Since its transition to Open Access in 1999, it has aimed to disseminate high-quality research, innovative practices, and critical insights relevant to mental health in Brazil and beyond. The journal's focus spans various topics in psychiatry, aiming to bridge the gap between research and clinical application, making it essential reading for professionals and academicians committed to improving mental health outcomes. With a commitment to fostering scholarly discourse, the Brazilian Journal of Psychiatry not only enriches the academic landscape but also enhances the practice of psychiatry through its widespread accessibility and dedication to excellence in research.
CNS DRUGS
Empowering Research for Better CNS TherapeuticsCNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.
Research on Child and Adolescent Psychopathology
Shaping the future of child and adolescent psychiatry.Research on Child and Adolescent Psychopathology, with ISSN 2730-7166 and E-ISSN 2730-7174, is a premier academic journal published by Springer, dedicated to advancing the understanding of psychological issues affecting children and adolescents. With an impressive Q1 ranking in both Developmental and Educational Psychology and Psychiatry and Mental Health in 2023, this journal serves as a crucial platform for researchers, practitioners, and students alike, focusing on evidence-based studies, innovative interventions, and the latest trends in child and adolescent mental health. As an Open Access journal, it ensures broader dissemination of knowledge, fostering collaboration and awareness among professionals across disciplines. Rooted in its commitment to tackling critical developmental challenges, Research on Child and Adolescent Psychopathology is not just a publication; it is a vital resource for those dedicated to improving mental health outcomes for young populations in the United States and beyond. Join the conversation as we explore new frontiers in understanding and addressing psychopathological issues.
Journal of the Korean Academy of Child and Adolescent Psychiatry
Fostering collaboration in mental health research.The Journal of the Korean Academy of Child and Adolescent Psychiatry (ISSN: 1225-729X; E-ISSN: 2233-9183) stands as a pivotal resource in the fields of child and adolescent mental health, contributing significantly to the dialogue on psychiatric practices and research in South Korea and beyond. Published by the KOREAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY, this journal is recognized for its dedication to advancing the understanding of psychiatric disorders that affect children and adolescents, as evidenced by its Q3 ranking in both Pediatrics, Perinatology and Child Health and Psychiatry and Mental Health categories for 2023. Operated from Seoul, South Korea, the journal facilitates knowledge-sharing among researchers and practitioners, providing insights into clinical practices and innovative treatment methodologies. Although not openly accessible, the journal emphasizes quality over quantity in its selection of studies, making each article a valuable contribution to the field. As the journal continues to publish impactful research through 2024, it remains essential reading for those committed to the well-being of younger populations and their families.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Pioneering Research for Evolving Psychopharmacological StrategiesJOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.
Neuropsychiatric Disease and Treatment
Pioneering Treatments for Complex Neuropsychiatric DisordersNeuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.
Journal of the Canadian Academy of Child and Adolescent Psychiatry
Exploring the intersection of pediatrics and mental health.Journal of the Canadian Academy of Child and Adolescent Psychiatry, published by the esteemed Canadian Academy of Child & Adolescent Psychiatry, serves as a crucial platform for scholarly discourse in the fields of Pediatrics and Psychiatry. With an ISSN of 1719-8429, this journal has been significantly contributing to the advancement of knowledge from 2006 to 2024, achieving notable recognition as a Q2 journal in both Pediatrics, Perinatology and Child Health, and Psychiatry and Mental Health categories. The journal's current Scopus rankings reflect its quality, sitting at the 70th percentile in Pediatrics and the 55th percentile in Psychiatry. Though currently not an open access journal, it provides valuable insights, research findings, and clinical implications for researchers, clinicians, and students dedicated to child and adolescent mental health. Its location in Canada underscores a commitment to advancing healthcare and mental wellness for young populations through rigorous academic inquiry.
Current Psychiatry Reports
Elevating standards in psychiatric research and practice.Current Psychiatry Reports, published by Springer, is a premier academic journal dedicated to the dissemination of cutting-edge research in the field of psychiatry and mental health. With a significant impact factor reflecting its esteemed position at Q1 in Psychiatry, this journal ranks an impressive #35 out of 567 in its category, placing it within the 93rd percentile of psychiatric publications as per Scopus metrics. Since its inception in 1996, it has provided a vital platform for clinicians, researchers, and students to explore and discuss contemporary psychiatric issues, advancements, and methodologies. While Current Psychiatry Reports is a subscription-based journal, its robust scholarly contributions are invaluable for practitioners and scholars looking to stay abreast of developments and empirical studies that shape the field. Based in the United States, at ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY 10004, it remains an authoritative source for evidence-based insights that guide both research and clinical practice in mental health.
ACTA PSYCHIATRICA SCANDINAVICA
Fostering Innovation in Mental Health PracticesACTA PSYCHIATRICA SCANDINAVICA is a leading journal in the field of Psychiatry and Mental Health, published by Wiley since its inception in 1926. With a strong commitment to advancing psychiatric research, this esteemed journal boasts an impressive impact factor and ranks within the top 7% of its category, reflecting its influence and relevance in the field. Operating without an Open Access model, the journal serves as a vital resource for professionals, researchers, and students keen on accessing high-quality, peer-reviewed studies focused on mental health issues. The scope of ACTA PSYCHIATRICA SCANDINAVICA spans a broad spectrum of psychiatric topics, providing a platform for groundbreaking research and clinical practice insights. Based in the United Kingdom and featuring contributions from experts worldwide, the journal continues to shape the future of psychiatric research through its rigorous publication standards and commitment to scholarly excellence.